Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03770273
Recruitment Status : Recruiting
First Posted : December 10, 2018
Last Update Posted : July 6, 2022
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) )

Brief Summary:


Mast cells help the body fight disease and heal wounds. People with indolent systemic mastocytosis (ISM) make too many mast cells. This causes pain, tiredness, digestive problems, and other symptoms. Researchers think the drug sarilumab could help.


To see if sarilumab is a safe and effective treatment for people with ISM.


Adults ages 18-75 with ISM who are enrolled in NIH study 02-I-0277


Participants will be screened with:

  • Physical exam
  • Medical history
  • Blood and urine tests
  • Questionnaires
  • Bone marrow removed by a needle inserted into the hip bone
  • Ultrasound of the abdomen
  • Photographs of the skin

Participants will repeat some screening tests at study visits.

Participants will have a baseline visit in the hospital for 3 days. They will:

  • Be assigned to get either the study drug or a placebo. They will not know which one they get.
  • Have a skin punch biopsy: An instrument will remove a small piece of skin.
  • Get their first drug dose injected under their skin

Participants will keep a side effect and medication diary during the study.

Participants will visit the clinic to get a drug dose every 2 weeks, for a total of 8 doses.

Participants will have a visit 2 weeks after their final dose. It will last up to 2 days.

Participants will have another visit 12 weeks later.

Participants may then continue this study for 1 more year. Those who continue will get sarilumab, even if they previously got the placebo, every 2 weeks. They will have visits every 6 weeks, and then every 3 months.

Condition or disease Intervention/treatment Phase
Indolent Systemic Mastocytosis Biological: Sarilumab Other: Placebo Phase 2

Detailed Description:

Systemic mastocytosis is a disorder caused by clonal mast cell proliferation and release of mast cell mediators including tryptase. As a result, mast cell numbers may increase and affect target organs including the dermis (maculopapular cutaneous mastocytosis/urticaria pigmentosa, flushing), gastrointestinal tract (abdominal pain, diarrhea), skeletal system (osteoporosis), hematological system (anemia, thrombocytopenia), and spleen and liver (organomegaly). Patients with indolent (non-aggressive) systemic mastocytosis (ISM) are not candidates for cytoreductive therapy and are generally treated with symptomatic therapy that only partly decreases symptoms. There is, however, a documented association between severity of mastocytosis and elevated serum levels of interleukin (IL)-6. Furthermore, mast cells have been shown to double their rate of division and exhibit increased reactivity and release of mediators when cultured in the presence of IL-6. In addition, in an animal model of mastocytosis, anti-IL-6 has been shown to slow disease progression. In this study, adults with ISM will thus be randomized and treated with sarilumab, a recombinant monoclonal antibody directed against the IL-6 receptor, or receive placebo. Sarilumab is marketed in the United States as Kevzara (Sanofi/Genzyme [Cambridge, MA, USA ]) and is approved by the Food and Drug Administration for the treatment of rheumatoid arthritis. Binding of sarilumab to the IL-6 receptor inhibits IL-6-associated human mast cell signaling and proliferation with a resultant decrease in proliferation and reactivity (decreased mediator release), and therefore is a rational choice for the treatment of ISM.

In this study, participants will be randomized with approximately half of the participants receiving study drug, which will be administered at 200 mg via subcutaneous (SC) injection once every 2 weeks (Q2W) for a total of 16 weeks. The other participants will receive a placebo administered via SC injection Q2W for 16 weeks. Participants will return for a follow-up visit 2 weeks after the final dose (treatment peak), and then again 12 weeks later. Evaluations at study visits will include quality of life and symptom assessments and measurement of serum tryptase levels. Bone marrow examination will be performed at the onset and conclusion of the study. After the week 28 visit, all participants will have the option to continue sarilumab for 52 more weeks, at 200 mg administered via SC injections. Participants will continue to be monitored on a regular basis for safety concerns, as instructed in the study drug s package insert.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2 Randomized Double-Blinded Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in Subjects With Indolent Systemic Mastocytosis
Actual Study Start Date : June 19, 2019
Estimated Primary Completion Date : August 1, 2024
Estimated Study Completion Date : August 1, 2024

Resource links provided by the National Library of Medicine

Drug Information available for: Sarilumab

Arm Intervention/treatment
Active Comparator: placebo
8 SC injections of placebo
Other: Placebo

Active Comparator: sarilumab
8 (SC) injections of 200 mg/1.14 mL of sarilumab over 16 weeks
Biological: Sarilumab
Sarilumab is a fully human anti-IL-6R-alpha monoclonal antibody that binds membrane-bound and soluble human IL-6R and has been shown to inhibit IL-6 signaling

Primary Outcome Measures :
  1. Frequency and severity of adverse events (AEs) [ Time Frame: day 0 through week 28 ]
    frequency and severity of adverse events during the randomized double-blinded placebo-controlled treatment period

  2. Mastocytosis Quality of Life Questionnaire (MC-QoL). [ Time Frame: 16 weeks post study drug initiation ]
    QoL at 16 weeks post-initiation of study drug/placebo using the Mastocytosis Quality of Life Questionnaire (MC-QoL).

Secondary Outcome Measures :
  1. mast cells in bone marrow and allelic frequency of D816V [ Time Frame: Day 0 and Week 16 for bone marrow and Day 0, week 16 and week 28 for D816V allelic Frequency ]
    Reduction of percentage infiltrating mast cells in bone marrow. Decrease in the allelic frequency of D816V using PCR

  2. Questionnaires MC-Qol, MSAS, SCORMA, MQLQ, MSAF [ Time Frame: Day 0 through Week 28 ]
    Percent improvement in QoL using MC-QoL, scoring of mastocytosis index (SCORMA), and Memorial Symptom Assessment Scale (MSAS) and the Mastocytosis Quality of Life Questionnaire (MQLQ), and the mastocytosis Symptom Assessment Form (MSAF)

  3. Reduction in use of medicines and reduction in serum Tryptase [ Time Frame: Day 0 through Week 28 ]
    Reduction in use of medicines for symptomatic relief, reduction in serum levels of tryptase

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 74 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Participants must meet all of the following criteria to be enrolled in this study:

  1. Male or female participant greater than or equal to 18 and < 75 years of age at screening.
  2. Enrolled on NIAID protocol 02-I-0277.
  3. Documented pathologic diagnosis of ISM.
  4. MC-QoL score of at least 25% (which suggests participant is at least somewhat affected by all McQoL questions).
  5. Willing and able to undergo a bone marrow biopsy and aspirate.
  6. Absolute neutrophil count (ANC) greater than or equal to 2000/mL.
  7. Hemoglobin greater than or equal to 12.0 g/dL (males), greater than or equal to 11 g/dL (females).
  8. Platelet count greater than or equal to 150,000/microliters.
  9. Alanine transaminase (ALT) and aspartate transaminase (AST) < 1.5 times the upper limit of normal (ULN).
  10. Willing to allow storage of blood and bone marrow for future use in medical research.
  11. Willing to allow genetic testing on biospecimens.
  12. Able to provide informed consent.
  13. Participants who can become pregnant must agree to use adequate contraception when engaging in sexual activities that can result in pregnancy. Adequate contraception must be used consistently, beginning at least 1 month before the beginning of dosing and lasting until 3 months after the final dose of study drug. Acceptable methods of contraception include the following:

    • Hormonal contraception (non-oral only).
    • Male or female condom with spermicide.
    • Diaphragm or cervical cap with a spermicide.
    • Intrauterine device.


Individuals meeting any of the following criteria will be excluded from study participation:

  1. Any abnormality that would be scored as a Grade 4 toxicity on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Only clinically significant lab results will deem the subject ineligible
  2. Infected with HIV or has other known immunodeficiency.
  3. Has an active infection, including localized infection.
  4. Active diverticulitis.
  5. Active or chronic viral hepatitis.
  6. Active or latent tuberculosis.
  7. Use of any other anti-IL-6 or anti-IL-6R agent within 1 year prior to the date informed consent was obtained.
  8. Use of cytoreductive therapy for mastocytosis within 1 year prior to the date informed consent was obtained.
  9. Known lymphoma or advanced and metastatic solid tumors on active therapy (including chemotherapy) within 1 year prior to the date informed consent was obtained
  10. Use of chemotherapy within 1 year prior to the date informed consent was obtained.
  11. Receipt of any marketed (eg, omalizumab) or investigational biologic or monoclonal antibody reported to affect mast cell activation within 5 half-lives prior to date informed consent was obtained.
  12. Receipt of intravenous (IV) immunoglobulin within 30 days prior to the date informed consent was obtained.
  13. Receipt of live attenuated vaccines within 30 days prior to the date informed consent was obtained.
  14. History of alcohol or drug/abuse within 12 months prior to date informed consent was obtained.
  15. Is allergic to any component of the sarilumab formulation.
  16. Pregnant or breastfeeding.
  17. Any condition that, in the opinion of the investigator, contraindicates participation in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03770273

Layout table for location contacts
Contact: Robin R. Eisch, R.N. (301) 443-1720
Contact: Hirsh D Komarow, M.D. (301) 594-2197

Layout table for location information
United States, Maryland
National Institutes of Health Clinical Center Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010   
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Layout table for investigator information
Principal Investigator: Hirsh D Komarow, M.D. National Institute of Allergy and Infectious Diseases (NIAID)
Additional Information:
Layout table for additonal information
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID) Identifier: NCT03770273    
Other Study ID Numbers: 190027
First Posted: December 10, 2018    Key Record Dates
Last Update Posted: July 6, 2022
Last Verified: June 27, 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) ):
Monoclonal Therapy
Mast Cell
Bone Marrow
Additional relevant MeSH terms:
Layout table for MeSH terms
Mastocytosis, Systemic
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Skin Diseases
Immune Complex Diseases
Immune System Diseases